Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H16N2S |
Molecular Weight | 232.345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](C1=CNC(=S)N1)C2=CC=CC(C)=C2C
InChI
InChIKey=WQXVKEDUCPMRRI-JTQLQIEISA-N
InChI=1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
Molecular Formula | C13H16N2S |
Molecular Weight | 232.345 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Rezatomidine (AGN 203818) is an alpha adrenergic receptor agonist that was developed for the treatment of chronic pain conditions. Phase II studies have evaluated the safety and effectiveness of rezatomidine in treating the pain in patients with fibromyalgia, irritable bowel syndrome, interstitial cystitis, and diabetic neuropathy. However, three studies were terminated early based on a business decision. Pancreatitis, gastric ulcer, viral infections and dehydration were reported as serious adverse events in patients when administered a 60mg dose.
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:25:33 GMT 2023
by
admin
on
Fri Dec 15 17:25:33 GMT 2023
|
Record UNII |
W5LMZ0RC8I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12143
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
9024
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
847829-38-3
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
11287722
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
C152207
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
W5LMZ0RC8I
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
SS-58
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107366
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
100000175228
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY | |||
|
DTXSID00233811
Created by
admin on Fri Dec 15 17:25:33 GMT 2023 , Edited by admin on Fri Dec 15 17:25:33 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|